Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AS

As of June 30, 2026, Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AS carries a market capitalization of 2.28B, placing it among publicly traded companies globally. Its enterprise value stands at 2.77B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AS has 220.00M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.82, and the price-to-book ratio stands at 1.26.

As of June 30, 2026, Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AS trades at an EV/EBITDA multiple of 45.71 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.42 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.77B versus a market cap of 2.28B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AS maintains a current ratio of 2.02, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 31.92, indicating elevated leverage, while an interest coverage ratio of 1.67 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AS posted a negative return on equity (ROE) of -17.29, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -12.67, reflecting losses generated across the asset base. The company generates approximately 3.34M in revenue per employee across its workforce of 242.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.99 indicates how many times Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AS sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AS recorded 46.05M in income tax expense. The company reported a pretax loss of -251.89M and -297.93M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AS's stock has declined approximately 43.15% over the past 52 weeks. The 50-day moving average sits at 8.13, while the 200-day moving average is 10.16.

Over the twelve months ended June 30, 2026, Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AS generated 809.85M in revenue and converted that into -297.93M in net income, yielding earnings per share of -1.35. EBITDA reached 60.68M, while operating income came in at -99.13M.

As of June 30, 2026, Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AS holds 84.11M in cash and equivalents against 576.34M in total debt, resulting in a net debt position of 473.67M. Total book value stands at 1.81B, with working capital of 364.48M providing operational flexibility.

Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AS produced 323.50M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -398.07M in capital expenditures, free cash flow totaled -74.57M - equivalent to -0.34 per share.

Over the twelve months ended June 30, 2026, Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AS posted a gross margin of 59.75, reflecting its pricing power and cost economics. The operating margin of -12.24 and net profit margin of -36.79 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -3.27: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -3.07, meaning Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AS raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AS's most recent stock split took place on May 18, 2023 with a 1:2 split ratio.

As of June 30, 2026, Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AS has an Altman Z-Score of 1.17, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.